Ignite Creation Date:
2025-12-25 @ 2:44 AM
Ignite Modification Date:
2026-03-09 @ 6:17 PM
Study NCT ID:
NCT03883633
Status:
COMPLETED
Last Update Posted:
2021-01-22
First Post:
2019-03-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Reversal of Cognitive Decline (ReCODE) Study
Sponsor:
QuesGen Systems Inc
Organization:
Study Overview
Official Title:
Reversal of Cognitive Decline (ReCODE) Study
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RECODE
Brief Summary:
Prospective study on patients enrolled in the ReCODE treatment protocol
Detailed Description:
The objective of the study is to determine if the ReCODE treatment has a measurable impact on the typical progression of neurocognitive decline observed in patients with Alzheimer's Disease (AD) and patients who are exhibiting Mild Cognitive Impairment (MCI). MCI is often a precursor to an AD diagnosis. For this study, there will be no distinction made between participants who have been diagnosed with AD and those who show signs of MCI.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: